Biomark Diagnostics receives BIAP funding
2015-03-31 08:03 ET - News Release Shares issued 48,835,040 Mr. Rashid Ahmed reports BIOMARK RECEIVES BIAP FUNDING FROM NRC-IRAP Biomark Diagnostics Inc. has been awarded by NRC-IRAP the business innovation access program (BIAP) funding for development and optimization of its novel recombinant antibodies. Rashid Ahmed, president and chief executive officer, commented: "This project will help optimize the potential production recombinant antibodies with work to be conducted by Dr. Bach at the University of British Columbia. These antibodies will be critical in the commercial development of our cancer diagnostic kits. We are excited to be able to develop the antibodies with rich features that can help secure source and quality necessary for medical application kit development." Biomark would like to thank both NRC and UBC for their help in this endeavour, that can yield both medical and economic benefit to Canada at large.